Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Deborah B. Leiderman"'
Publikováno v:
Neuropharmacology. 142
Scientific curiosity and fascination have played a key role in human research with psychedelics along with the hope that perceptual alterations and heightened insight could benefit well-being and play a role in the treatment of various neuropsychiatr
Publikováno v:
Clinical pharmacology and therapeutics. 103(4)
Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining
Autor:
Sharon Hertz, Michael Klein, Gary M. Reisfield, James P. Zacny, George E. Bigelow, Laurie B. Burke, Shannon M. Smith, Robert D. Colucci, Ernest A. Kopecky, Sharon L. Walsh, Cristina Sampaio, Srinivasa N. Raja, Robert L. Balster, Richard A. Denisco, John T. Farrar, Edgar H. Adams, Edward J. Cone, Bob A. Rappaport, Deborah B. Leiderman, Pamela Palmer, Beatrice Setnik, Sandra D. Comer, Dennis C. Turk, Nathaniel P. Katz, Penney Cowan, Jennifer A. Haythornthwaite, Richard W. Foltin, Joseph W. Stauffer, Michael P. McDermott, Michael C. Rowbotham, Kelly Posner, Robert H. Dworkin, Marta Sokolowska, Alec B. O'Connor, Charles A. O'Brien, Christine Rauschkolb, J. David Haddox, Roderick Junor, Gary W. Jay
Publikováno v:
Pain. 154:2324-2334
Assessing and mitigating the abuse liability (AL) of analgesics is an urgent clinical and societal problem. Analgesics have traditionally been assessed in randomized clinical trials (RCTs) designed to demonstrate analgesic efficacy relative to placeb
Autor:
Deborah B. Leiderman
Publikováno v:
Drug and Alcohol Dependence. 105:S9-S13
This paper summarizes the background and origins of pharmaceutical risk management and minimization principles and approaches as reflected in FDA statute, policy, and practice. It describes the history of early "risk management" programs, such as the
Autor:
Domenic A. Ciraulo, Joseph S. LoCastro, Ahmed Elkashef, Ann Marie Ciraulo, Ofra Sarid-Segal, Clifford M. Knapp, Daniel A. Bloch, Deborah B. Leiderman, Margaret A. Montgomery
Publikováno v:
Addiction. 100:12-22
Aims The two studies presented here were conducted to assess the efficacy of paroxetine, pentoxifylline, riluzole, venlafaxine and pramipexole as medications for the treatment of cocaine dependence. Design A multi-arm, modified blinded, placebo-contr
Autor:
David J. Greenblatt, Deborah B. Leiderman, John Rotrosen, Joseph S. LoCastro, Clifford M. Knapp, Ofra Sarid-Segal, Domenic A. Ciraulo, Ann Marie Ciraulo
Publikováno v:
Addiction. 100:23-31
Aims In the current study, nefazodone, an antidepressant with dual action on serotonin and norepinephrine reuptake as well as 5-HT2A receptor antagonist effects, was studied in subjects with cocaine dependence and depressive symptoms, to determine it
Autor:
Peter T. Bridge, Deborah B. Leiderman, Daniel A. Bloch, Joseph S. LoCastro, Eugene Somoza, Philip W. Lavori
Publikováno v:
Journal of Clinical Psychopharmacology. 19:246-256
Increased interest in addiction psychopharmacology has raised unique methodologic issues in the design, conduct, and analysis of outcomes in clinical trials of therapeutic agents for drug dependence. This article summarizes issues raised at a meeting
Autor:
Deborah B. Leiderman, Edward B. Bromfield, William H. Theodore, Susumu Sato, Marshall Balish, Peter Herscovitch
Publikováno v:
Epilepsia. 37:796-802
To study quantitative alterations in regional cerebral blood flow (rCBF) accompanying seizures, and to assess the utility of ictal activation PET scanning as a noninvasive clinical tool for localization of epileptogenic foci, we used pentylenetetrazo
Autor:
J. David Haddox, Nathaniel P. Katz, Penney Cowan, Chris Ellyn Johanson, Robert L. Balster, John T. Farrar, Bob A. Rappaport, Deborah B. Leiderman, Edward J. Cone, Michael P. McDermott, Michael C. Rowbotham, Sharon L. Walsh, Sandra D. Comer, Roderick Junor, Marta Sokolowska, Pamela Palmer, James P. Zacny, Sharon Hertz, Igor Cerny, Edgar H. Adams, Gary W. Jay, Donald R. Jasinski, Robert H. Dworkin, Christine Rauschkolb, Cristina Sampaio, Charles A. O'Brien, Alec B. O'Connor, Richard W. Foltin, Michael Klein, Laurie B. Burke, Beatrice Setnik, Srinivasa N. Raja, Jennifer A. Haythornthwaite, Dennis C. Turk, George E. Bigelow, Robert D. Colucci, Ernest A. Kopecky, Joseph W. Stauffer, Edward M. Sellers
Publikováno v:
Pain, vol 153, iss 12
A critical component in development of opioid analgesics is assessment of their abuse liability (AL). Standardization of approaches and measures used in assessing AL have the potential to facilitate comparisons across studies, research laboratories,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fc797cb46ae09367de20754e0b5b2b1
https://escholarship.org/uc/item/57w4w2f2
https://escholarship.org/uc/item/57w4w2f2
Autor:
Deborah B. Leiderman, William H. Theodore, Karen Lloyd-Hontz, Imran Khan, Pat Reeves, William D. Gaillard
Publikováno v:
Epilepsy Research. 16:51-54
We used positron emission tomography with [15O]water and [18F]fluoro-2-deoxyglucose (FDG) to study the effect of naloxone on cerebral blood flow (CBF) and glucose metabolism (LCMRglc) in patients with complex partial seizures. There was no effect on